Special issues in myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 28-35

  Barbui, Tiziano ^b   Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

Bleeding; Children; Chronic myeloproliferative neoplasms; Essential thrombocythemia; Hydroxyurea; Leukemic transformation; MPN; Pediatric patients; Polycythemia vera; Pregnancy; Primary myelofibrosis; Pruritus; Splanchnic vein thrombosis; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; CYPROHEPTADINE; DESMOPRESSIN; HEPARIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAROXETINE; PEGINTERFERON; PIPOBROMAN; PSORALEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOPLASTY; ANTEPARTUM HEMORRHAGE; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW CANCER; BRAIN HEMORRHAGE; BUDD CHIARI SYNDROME; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEMARTHROSIS; HEPARINIZATION; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LEUKEMOGENESIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MENTAL DISEASE; MESENTERIC VEIN THROMBOSIS; MUCOSAL BLEEDING; MUSCLE HEMATOMA; MUTAGENICITY; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHOTOCHEMOTHERAPY; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRURITUS; RETROPERITONEAL HEMORRHAGE; REYE SYNDROME; RISK REDUCTION; SKIN BLEEDING; SPLANCHNIC VEIN THROMBOSIS; SPLENECTOMY; SPONTANEOUS ABORTION; TERATOGENICITY; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS PREVENTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; ULTRAVIOLET A RADIATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; FEMALE; HEMORRHAGE; HUMANS; HYDROXYUREA; MYELOPROLIFERATIVE DISORDERS; PREGNANCY; PRURITUS; VENOUS THROMBOSIS;

EID: 79551482258     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0073-7     Document Type: Article

References (50)

1. • Barbui T, Barosi G, Birgegard G, et al.: Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011 (in press). These are the most up-to-date management recommendations for Philadelphia-negative classic myeloproliferative neoplasms, based on the results of a systematic consensus process by a panel of 21 experts appointed by the European LeukemiaNet.
2. C Harrison 2005 Pregnancy and its management in the Philadelphia negative myeloproliferative diseases Br J Haematol 129 293 306 1:CAS:528: DC%2BD2MXltlWnt7Y%3D 10.1111/j.1365-2141.2005.05400.x 15842653 (Pubitemid 40646888)
3. M Griesshammer S Struve CM Harrison 2006 Essential Thrombocythemia/ Polycythemia Vera and pregnancy: the need for an observational study in Europe Semin Thromb Haemost 32 422 429 10.1055/s-2006-942763
4. T Barbui G Barosi A Grossi, et al. 2004 Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica 89 215 32 1:CAS:528: DC%2BD2cXotlSrt7Y%3D 15003898
5. MA Elliott A Tefferi 2003 Thrombocythaemia and pregnancy Best Pract Res Clin Hematol 16 227 242 10.1016/S1521-6926(03)00019-7
6. N Gangat AP Wolanskyj S Schwager A Tefferi 2009 Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies Eur J Haematol 82 350 353 10.1111/j.1600-0609.2009.01214.x 19243425
7. F Passamonti ML Randi E Rumi, et al. 2007 Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation Blood 110 485 489 1:CAS:528:DC%2BD2sXot1emsbw%3D 10.1182/blood-2007-01-071068 17426257 (Pubitemid 47105385)
8. S Robinson S Bewley BJ Hunt DH Radia CN Harrison 2005 The management and outcome of 18 pregnancies in women with polycythemia vera Haematologica 90 1477 83 16266894
9. CN Harrison D Bareford N Butt, et al. 2010 Guideline for investigation and management of adults and children presenting with a thrombocytosis Br J Haematol 149 352 375 1:CAS:528:DC%2BC3cXms1Oqu7c%3D 10.1111/j.1365-2141.2010. 08122.x 20331456 This recent and comprehensive guideline produced by the British Committee for Standards in Haematology provides health care professionals with clear guidance on the investigation and management of thrombocytosis in both adult and pediatric patients
10. A Tefferi F Passamonti 2009 Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations Am J Hematol 84 629 630 10.1002/ajh.21508 19731306
11. C Dame AH Sutor 2005 Primary and secondary thrombocytosis in childhood Br J Haematol 129 165 177 1:CAS:528:DC%2BD2MXktl2htbY%3D 10.1111/j.1365-2141.2004. 05329.x 15813844 (Pubitemid 40562437)
12. ED Belay JS Bresee RC Holman, et al. 1999 Reye's syndrome in the United States from 1981 through 1997 N Engl J Med 340 1377 1382 1:STN:280: DyaK1M3ivValsQ%3D%3D 10.1056/NEJM199905063401801 10228187 (Pubitemid 29205400)
13. RT Chung AJ Iafrate PC Amrein, et al. 2006 Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention N Engl J Med 354 2166 75 1:CAS:528:DC%2BD28XkslCrsbk%3D 10.1056/NEJMcpc069006 16707754 (Pubitemid 43736617)
14. Y Chait B Condat D Cazals-Hatem, et al. 2005 Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis Br J Haematol 129 553 560 10.1111/j.1365-2141.2005. 05490.x 15877740 (Pubitemid 40769907)
15. RK Patel N Lea A Heneghan, et al. 2006 Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome Gastroenterology 130 2031 8 1:CAS:528:DC%2BD28XntVWitr4%3D 10.1053/j.gastro.2006.04.008 16762626 (Pubitemid 43816970)
16. JJ Kiladjian F Cervantes FWG Leebek, et al. 2008 The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood 111 4922 4929 1:CAS:528:DC%2BD1cXmtlaiurs%3D 10.1182/blood-2007-11-125328 18250227
17. I Martinelli M Franchini PM Mannucci 2008 How I treat rare venous thrombosis Blood 112 4818 4823 1:CAS:528:DC%2BD1cXhsFWms7%2FI 10.1182/blood-2008-07-165969 18805965
18. B Condat F Pessione S Hillaire, et al. 2001 Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy Gastroenterology 120 490 7 1:STN:280:DC%2BD3M7otVKnsw%3D%3D 10.1053/gast.2001. 21209 11159889
19. KV Narayanan Menon V Shah PS Kamath 2004 The Budd-Chiari syndrome N Engl J Med 350 578 585 10.1056/NEJMra020282 (Pubitemid 38160788)
20. R Landolfi R Marchioli J Kutti, et al. 2004 Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 114 124 1:CAS:528:DC%2BD2cXjs1aluw%3D%3D 10.1056/NEJMoa035572 14711910 (Pubitemid 38056222)
21. R Marchioli G Finazzi R Landolfi, et al. 2005 Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2224 32 10.1200/JCO.2005.07.062 15710945 (Pubitemid 46218714)
22. CN Harrison PJ Campbell G Buck, et al. 2005 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 33 45 1:CAS:528:DC%2BD2MXmtVWjsbs%3D 10.1056/NEJMoa043800 16000354 (Pubitemid 41007805)
23. MA Elliott A Tefferi 2005 Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia Br J Haematol 128 275 90 1:STN:280:DC%2BD2M%2FktVSntg%3D%3D 10.1111/j.1365-2141.2004.05277.x 15667529 (Pubitemid 40216149)
24. R Landolfi MC Cipriani L Novarese 2006 Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention Best Pract Res Clinical Haematol 19 617 33 1:CAS:528: DC%2BD28Xls1aqurc%3D 10.1016/j.beha.2005.07.011 (Pubitemid 43863144)
25. AI Schafer 2006 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood 107 4214 22 1:CAS:528:DC%2BD28Xlt1Cgsrc%3D 10.1182/blood-2005-08-3526 16484586 (Pubitemid 43801343)
26. AJ Wagstaff GM Keating 2006 Anagrelide. A review of its use in the management of essential thrombocythemia Drugs 66 111 31 1:CAS:528: DC%2BD28XhslWqtr4%3D 10.2165/00003495-200666010-00006 16398570 (Pubitemid 43148990)
27. JS Cervera AV Mena-Duran CS Piqueras 2005 The use of recombinant factor VIIa in a patient with essential thrombocythemia with uncontrolled surgical bleeding Thromb Haemost 93 383 384 1:CAS:528:DC%2BD2MXhs1Kns7c%3D 15711760
28. M Ruggeri F Rodeghiero A Tosetto, et al. 2008 Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey Blood 111 666 671 1:CAS:528:DC%2BD1cXns1Cnug%3D%3D 10.1182/blood-2007-07- 102665 17909074
29. RA Mesa 2009 How I treat symptomatic splenomegaly in patients with myelofibrosis Blood 113 5394 5400 1:CAS:528:DC%2BD1MXntVertLg%3D 10.1182/blood-2009-02-195974 19332765
30. ML Randi F Fabris E Ruzzon, et al. 2002 Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia Haematologica 87 1180 4 12414348
31. A Tefferi RA Mesa DM Nagorney, et al. 2000 Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients Blood 95 226 33
32. KS Saini MM Patnaik A Tefferi 2010 Polycythemia Vera-associated pruritus and its management Eur J Clin Invest 40 828 834 10.1111/j.1365-2362.2010.02334.x 20597963
33. L Pieri C Bogani P Guglielmelli, et al. 2009 The JAK2V617F mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera Haematologica 94 1484 1488 10.3324/haematol. 2009.007047
34. S Verstovsek H Kantarjian RA Mesa, et al. 2010 Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 1117 1127 1:CAS:528:DC%2BC3cXhtFOltrjJ 10.1056/NEJMoa1002028 20843246 The first phase I/II clinical trial of a selective JAK2 inhibitor published in full, showing marked and durable clinical benefits in patients with myelofibrosis
35. Vannucchi AM, Guglielmelli P, Gattoni E, et al.: RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF). [abstract 307]. Presented at the 51th American Society of Hematology Congress, New Orleans, Louisiana, December 5-8, 2009.
36. A Rambaldi CM Dellacasa G Finazzi, et al. 2010 A pilot study of the hystone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Br J Haematol 150 446 455 1:CAS:528:DC%2BC3cXhtFCru77L 20560970
37. Landaw SA. Acute leukemia in polycythemia vera. In Polycythyemia Vera and the Myeloproliferative Disorders. Edited by Wasserman LR, Berk PD, Berlin NI. Philadelhia: WP Saunders Co. 1995:154-165.
38. T Barbui 2004 The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 41 Suppl 3 15 17 10.1053/j.seminhematol.2004. 02.006 15190518
39. S Cortelazzo G Finazzi M Ruggeri, et al. 1995 Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial N Engl J Med 332 1132 1136 1:STN:280: DyaK2M3hsVKkuw%3D%3D 10.1056/NEJM199504273321704 7700286
40. G Finazzi T Barbui 2007 How I treat patients with polycythemia vera Blood 109 5104 11 1:CAS:528:DC%2BD2sXmslOku70%3D 10.1182/blood-2006-12-038968 17264301 (Pubitemid 46890524)
41. N Gangat AP Wolanskyi McClure, et al. 2007 Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients Leukemia 21 270 276 1:STN:280: DC%2BD2s%2Fks1ejtA%3D%3D 10.1038/sj.leu.2404500 17170720 (Pubitemid 46158119)
42. G Finazzi V Caruso R Marchioli, et al. 2005 Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study Blood 105 2664 2670 1:CAS:528:DC%2BD2MXivFGmsbg%3D 10.1182/blood-2004-09-3426 15585653 (Pubitemid 40446255)
43. Bjorkholm M, Derolf AR, Ekstrand C, et al.: Clinical risk for AML/MDS transformation in Philadelphia negative chronic myeloproliferative neoplasms. A population-based nested case-control study in Sweden [abstract 1085]. Presented at the 14th European Hematology Association Congress, Berlin, June 4-7, 2009.
44. S Lanzkron JJ Strouse R Wilson, et al. 2008 Systematic review: hydroxyurea for the treatment of adults with sickle cell disease Ann Intern Med 148 939 955 18458272
45. Kiladjian JJ, Chevret S, Dosquet C, et al.: Long-term outcome in polycythemia vera: final analysis of a randomized trial comparing hydroxyurea (HU) to Pipobroman (Pi). [abstract 1746]. Presented at the 50th American Society of Hematology Congress, San Francisco, California, December 6-9, 2008.
46. Y Sterkers C Preudhomme JL Lai, et al. 1998 Acute myeloid leukemia and myelodisplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion Blood 91 616 622 1:CAS:528:DyaK1cXjsVWisQ%3D%3D 9427717
47. A Tefferi J Thiele A Orazi, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092 1097 1:CAS:528: DC%2BD2sXptFKmurg%3D 10.1182/blood-2007-04-083501 17488875 (Pubitemid 47281402)
48. PJ Campbell EJ Baxter PA Beer, et al. 2006 Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood 108 3548 3555 1:CAS:528:DC%2BD28Xht1ahsL3P 10.1182/blood-2005-12-013748 16873677
49. RA Mesa CY Li RP Ketterling, et al. 2005 Leukemic transformation in myelofibrosis with myeloid metaplasia: a single institution experience with 91 cases Blood 105 973 977 1:CAS:528:DC%2BD2MXhtFCgsLg%3D 10.1182/blood-2004-07- 2864 15388582 (Pubitemid 40170863)
50. CS Tam Rm Nussenzveig U Popat, et al. 2008 The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms Blood 112 1628 1637 1:CAS:528:DC%2BD1cXhtVylu77P 10.1182/blood-2008-02-138230 18566326